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doi:10.1Objective: There are potentially deleterious sequelae of the physiologic response to surgical intervention. Some
inflammatory cytokines can act as tumor growth factors, angiogenic and metastatic promoters, or both. Modula-
tion of negative effects could improve outcomes from surgical intervention. The effects of surgical intervention on
gene expression have not been fully elucidated. We assayed gene expression changes in an animal model of tho-
racotomy versus a sham operation and evaluated the ability of a cyclooxygenase inhibitor, celecoxib, to mediate
these changes.
Methods: Sixty adult male BALB/c mice were randomized into one of 3 experimental groups: sham operation
with anesthesia only, thoracotomy incision, and thoracotomy incision with perioperative celecoxib administra-
tion. Six hours after surgical intervention, the animals were killed, and blood was collected. RNA pools from
each group were labeled and hybridized to Mouse Whole Genome Microarrays. Gene expression profiles were
analyzed to determine the effect of both surgical intervention and celecoxib treatment.
Results: Surgical intervention initiated a robust gene expression response. We identified 867 transcripts that were
found to be statistically significant (corrected P< .05) and differentially expressed at least 2-fold in response to
surgical intervention. Celecoxib had a profound effect on this response, preserving close to baseline levels of ex-
pression for most of those genes.
Conclusions: Surgical intervention has a dramatic effect on the expression of genes related to the inflammatory
response. Perioperative treatment with a cyclooxygenase 2 inhibitor abated many of these changes and might
counteract many of the negative effects of the response to surgical intervention. (J Thorac Cardiovasc Surg
2010;139:1253-60)E
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SSupplemental material is available online.
Surgical procedures elicit trauma-related changes in what is
known as the ‘‘surgical stress response.’’ Typically, surgical
intervention induces activation of immune cells and subse-
quent release of various cytokines, which have far-
reaching systemic effects. Initially, cytokines are produced
by monocytes and macrophages at the local site of injury,1
but this is followed by participation of peripherally recruited
leukocytes. This cytokine cascade plays a significant role in
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The Journal of Thoracic and Carnormalizes within a few days of the surgical injury, as deter-
mined based on measurement of inflammatory mediators.3,4
Cytokines mediate cell signaling through initiation, am-
plification, and perpetuation of the inflammatory response
at the local and systemic levels. Many of these signals are
proinflammatory. Several attempts have been made to illus-
trate the effect of surgical intervention on the inflammatory
response in peripheral blood using cytokines, either in se-
rum3-5 or by assessment of cytokine mRNA in blood
monocytes.6 However, precise characterization of this re-
sponse, particularly at the molecular level, has been limited
because of the small number of markers examined and
largely inconclusive results. The outcomes of these experi-
ments vary by the temporal specificity of peak cytokine ex-
pression,3-5,7 the magnitude of the surgical procedure,3,5,8
and the tissue in which the response was assessed.9
Both anesthesia and the act of surgical intervention itself
result in significant immunosuppression,10 which can have
important consequences for surgical resection of cancers.
Much of the inflammatory response at the time of surgical
intervention has been suggested to have a negative effect
in terms of metastasis and tumor recurrence.8,11
Furthermore, surgeons have historically not used systemic
anticancer therapies during the perioperative period for
fear of interfering with a successful surgical outcome. Thediovascular Surgery c Volume 139, Number 5 1253
Abbreviations and Acronyms
COX-2 ¼ cyclooxygenase 2
IFN-g ¼ interferon g
NK ¼ natural killer
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Simmune suppression of surgical intervention and anesthesia
coupled with the lack of any systemic therapy in the
perioperative period leaves the patient vulnerable to the
establishment of micrometastatic deposits or to growth of
established metastases. Indeed, it has been suggested that
this vulnerability could also activate an angiogenic switch
for quiescent metastases. The perioperative administration
of an agent that could alleviate the negative impact of
surgical intervention and provide some systemic therapeutic
oversight has the potential to improve survival after surgical
intervention. One promising group of compounds with the
potential for use at the time of surgical intervention is the
cyclooxygenase 2 (COX-2) inhibitors. The COX-2 enzyme
is upregulated by surgical stress and appears to modulate
many of the inflammatory pathways after surgical interven-
tion. It is also known to occur in many cancers, including
non–small cell lung cancer.12 The COX-2 inhibitor, cele-
coxib, was developed to provide anti-inflammatory and anal-
gesic benefits to patients with severe arthritic pain. It has little
effect on bleeding or renal dysfunction and does not appear to
have significant cardiovascular side effects, especially when
used for limited periods of time.13 It also demonstrates pro-
found anticancer effects through mechanisms that involve ap-
optosis and the inhibition of angiogenesis and metastasis.14
The aims of this experiment were to (1) more precisely
characterize the systemic inflammatory response to surgical
intervention at the genomic level and (2) determine the po-
tential for pharmacologic modulation of that response using
a compound, celecoxib, known to have both anti-
inflammatory and anticancer benefits. To achieve these
goals, we performed whole-genome gene expression micro-
array analysis on mice that had been subjected to anesthesia
alone (group A), anesthesia and a surgical procedure (group
AS), and anesthesia and a surgical procedure with the addi-
tion of perioperative administration of celecoxib (group
ACS). Gene expression analysis quantifies the activity of
a gene by measuring the number of transcripts being pro-
duced under a given experimental condition, and the use
of microarrays permits the evaluation of all known genes
in a single experiment, making the identification of inflam-
matory pathways substantially more robust than has previ-
ously been possible. Our goal was to elucidate potentially
deleterious aspects of the response to surgical intervention
and determine whether we could modulate those effects
through the use of a COX-2 inhibitor known to have antitu-
mor activity to ascertain its potential clinical utility.1254 The Journal of Thoracic and Cardiovascular SurMATERIALS AND METHODS
Animals and Treatments
Sixty 5- to 6-week-old male BALB/cAnNTac mice were obtained from
Taconic Farms, Inc (Germantown, NY), and acclimated for 8 days. The
mice were housed 4 per cage in Thoren polycarbonate maxi-miser cages
and racks (Lithgow Laboratory Services, Las Vegas, Nev) with Aspen
Sani-chips (Harlan Teklan, Madison, Wis). They were fed Purina Lab
diet for rodents and given sterile water for irrigation. The animal rooms
were maintained at 20C to 23C and 48% to 53% relative humidity
with a 12/12-hour light/dark cycle. Mice were randomized into 3 groups
of 20. Group A underwent a ‘‘sham’’ operation (anesthesia only). Group
AS underwent a thoracotomy incision, a procedure that mimics the surgical
stress of an actual thoracotomy without opening the pleural cavity, thus pre-
venting pneumothorax. Group ACS was administered perioperative cele-
coxib (lot no. C070030; G.D. Searl LLC, New York, NY) treatment (100
mg/kg by weight per day by means of oral gavage) for 3 days, followed
by a thoracotomy incision. All surgical procedures were performed after
achievement of anesthesia (through intraperitoneal injection with ket-
amine/xylazine) by a board-certified thoracic surgeon. Anesthesia protocols
for all groups were consistent. Six hours after surgical intervention, anesthe-
sia was readministered, and cardiac puncture was performed to collect
blood. The 6-hour postoperative time point was chosen based on available
data for assessing the systemic response to injury.3-8,11
Isolation of High-Quality RNA
Bloodwas immediately processed for isolation of total RNAby using the
Mouse RiboPure Blood RNA Isolation Kit (Ambion, Austin, Tex), accord-
ing to the manufacturer’s specifications. The 60 individual RNAs were
quantified in triplicate by using the Quant-it RNA Assay Kit and Qubit
flourometer (Invitrogen, Carlsbad, Calif), according to the manufacturer’s
specifications. Absorbance at 260/280 and 260/230 was measured to assess
RNA quality, and the best 16 RNA samples from each group were pooled in
equimolar concentrations to create a single RNA pool per group. Each of the
3 resulting RNA pools was diluted to 50 ng/mL and assessed on an Agilent
2100 bioanalyzer (Agilent, Foster City, Calif) to ensure only RNA of the
highest integrity was used for subsequent microarray analysis.
Microarray Analysis
Each of the 3 RNA pools was labeled and hybridized (in quadruplicate)
to Agilent 4x44K One-Color Whole Mouse Genome Oligo Microarrays,
scanned on an Agilent Microarray Scanner (model G2505B), and processed
with Agilent’s Feature Extraction software (version 9.5.1). All arrays were
quality controlled (ie, normalized) for a minimum median hybridization in-
tensity with GeneSpring 10.0.2 software (Agilent). One of the 4 technical
replicates for group 3 displayed significant amounts of error and was re-
moved from further analysis. Expression of each gene was averaged across
technical replicates. Unpaired t tests were used to determine gene expression
differences between groups by using the false discovery rate multiple testing
correction.15 Statistically significant entities were assessed for a minimum
2-fold change in GeneSpring version 10.0.2. Because multiple probes can
be used to assess the presence or absence of individual genes on a microar-
ray, data will be described in both/either terms of transcripts (ie, probes),
genes, or both, depending on the context. A flowchart of the experimental
design for this investigation can be seen in Figure 1.RESULTS
Patterns of Gene Expression Associated With
Surgical Intervention and Celecoxib Administration
High-quality, robust gene expression data were obtained
for all 3 experimental groups at the chosen 6-hour time point,
and a total of 948 differentially expressed transcripts weregery c May 2010
FIGURE 1. A flowchart of the experimental design outlined in this study.
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Sidentified at a 99% confidence interval. Comparison of the
surgical intervention group (group AS) with the baseline
group (group A) identified 867 transcripts (770 genes) thatFIGURE 2. Expression profile showing the normalized intensity values of 867 t
and differentially expressed at least 2-fold at 6 hours after surgical intervention i
(Post-Surgery) compared with a group of mice subjected to anesthesia only (SHA
the COX-2 inhibitor celecoxib. The colored lines in these profile plots indicate the
displayed in the orange-to-red spectrum, decreases in gene expression display
displayed in yellow.
The Journal of Thoracic and Carwere found to be statistically significant (corrected
P< .05) and differentially expressed at least 2-fold. The
vast majority of these transcripts (769) were upregulated in
response to surgical intervention, with only 98 being down-
regulated. Perioperative administration of celecoxib had
a dramatic effect on gene expression changes induced by
surgical intervention. Contrast of the expression pattern of
the 867 transcripts differentially expressed in the surgical in-
tervention group to that of the same 867 transcripts in the
celecoxib-treated group can be seen in Figure 2. The surgi-
cally induced increase in gene expression (Figure 2, A)
was significantly modulated by the perioperative administra-
tion of the COX-2 inhibitor (Figure 2, B).
Comparison of the celecoxib-treated surgical intervention
group (group ACS) with the baseline group (group A) iden-
tified 216 transcripts (190 genes) that were found to be sta-
tistically significant (corrected P< .05) and differentially
expressed at least 2-fold, of which 199 were upregulated
and 17 were downregulated. A Venn diagram showing the
relationship between our 2 experimental groups can be
seen in Figure 3. This analysis revealed 3 distinct sets of
genes: those that are differentially expressed only in re-
sponse to surgical intervention alone (732 transcripts), those
that are differentially expressed in response to both surgical
intervention and celecoxib treatment (135 transcripts), and
those that, by inference, are differentially expressed in
response to celecoxib treatment alone (81 transcripts). A
2-dimensional unsupervised hierarchical clustering was
performed on the 948 differentially expressed transcriptsranscripts (770 genes) found to be statistically significant (corrected P<.05)
n a group of mice subjected to anesthesia followed by a surgical procedure
M). A, No perioperative treatment. B, With perioperative administration of
direction of gene regulation (up or down), with increases in gene expression
ed in the green-to-blue spectrum, and marginal gene expression changes
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FIGURE 3. A Venn diagram showing the relationship between our 2 ex-
perimental groups. The red circle (right) represents the 867 transcripts found
to be statistically significant (corrected P<.05) and differentially expressed
at least 2-fold at 6 hours after surgical intervention in a group of mice sub-
jected to surgery alone (group AS). The blue circle (left) represents the 216
transcripts found to be statistically significant (corrected P<.05) and differ-
entially expressed at least 2-fold at 6 hours after surgical intervention in
a group of mice subjected to surgical intervention but given perioperative
administration of the COX-2 inhibitor celecoxib (group ACS). This analysis
revealed 3 distinct sets of genes: those that are differentially expressed only
in response to surgical intervention alone (732 transcripts), those that are
differentially expressed in response to both surgical intervention and cele-
coxib treatment (135 transcripts), and those that, by inference, are differen-
tially expressed in response to celecoxib treatment alone (81 transcripts).
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Sto more precisely demonstrate the relationship among the 3
experimental groups (Figure 4). This tool groups genes, ex-
perimental conditions, or both into clusters based on the sim-
ilarity of their expression patterns.16 Using this approach, we
demonstrated that the gene expression pattern of the
celecoxib-treated surgical intervention group (group ACS)
is more similar to that of the baseline anesthesia group
(group A) than that of the surgical intervention–only group
(group AS). This pattern of clustering was further confirmed
by means of principal component analysis (data not shown).Characterization of the Inflammatory Response
Initiated by Surgical Intervention Alone
(Comparison of Group AS With Group A)
Because our prime directive was the inflammatory re-
sponse, we focused our analysis on known inflammatory
transcripts. Of the approximately 200 known inflammatory
transcripts found to be differentially expressed at 6 hours af-
ter surgical intervention, 10 chemokine and 5 chemokine re-
ceptor genes, as well as 7 interleukin receptor genes, were
identified. Among commonly studied cytokines, only the
gene encoding interferon g (IFN-g) was differentially ex-
pressed at the 6-hour time point in this survey. It should
be noted that most of the genes identified in these experi-
ments could not be appropriately addressed in this treatise1256 The Journal of Thoracic and Cardiovascular Surbecause of space limitations. However, a partial list of the
inflammatory genes that were differentially expressed in
response to surgical intervention can be found in Table 1.
Effect of Perioperative Celecoxib Administration on
Surgical Intervention (Comparison of Group ACS
With Group A)
Only about 50 of the approximately 200 known inflam-
matory transcripts were differentially expressed in the group
that received a regimen of celecoxib during the perioperative
period compared with the baseline group, indicating that cel-
ecoxib successfully mitigated much of the inflammatory re-
sponse after surgical intervention. The biggest difference in
expressionwas seen in the chemokineCcl25, in which a tran-
script that was 39.4-fold increased in response to surgical in-
tervention (group AS) was 2.5-fold decreased with the
addition of perioperatively administered celecoxib (group
ACS).
DISCUSSION
As proof of concept for a similar study attempting to char-
acterize the systemic effects of surgical intervention at the
whole-genome level in human subjects, we performed a pilot
study comparing the gene expression profile of a group of
mice subjected to anesthesia (group A) with that of a group
of mice subjected to anesthesia followed by a surgical pro-
cedure (group AS). We assessed gene expression at 6 hours
after surgical intervention, a time point chosen to reflect the
early systemic response to surgical injury. By using animals
treated with anesthesia only as our baseline group, we aimed
to detect only those changes that are due to the surgical pro-
cedure itself. Furthermore, we attempted to understand the
potential of the COX-2 inhibitor celecoxib to modulate
this systemic response at the genomic level.
Characterization of the Inflammatory Response
Initiated by Surgical Intervention Alone (Group AS)
Our survey identified 867 transcripts (770 genes) that dis-
played statistically significant differences in the surgical in-
tervention group (corrected P<.05) and were at least 2-fold
differentially expressed. Most of the transcripts (88.7%)
showed a dramatic increase in expression in response to
the surgical procedure; however, some (11.3%) were shown
to have decreases in expression (Figure 2, A). Our analyses
detected 15 chemokine-related genes (both chemokines and
their receptors), suggesting that they are important mediators
of the surgical stress response. Chemokines are a superfamily
of proinflammatory polypeptide cytokines that selectively
attract and activate different cell types (ie, chemotaxis) in re-
sponse to coordination by IFN-g. Despite the importance of
chemokines in immune cell recruitment, there have been no
studies to our knowledge on the temporal expression of che-
mokines after surgical trauma. The 2most upregulated genes
in our survey, the chemokines Ccl21 and Ccl25, are potentgery c May 2010
FIGURE 4. A heat map representing the 2-dimensional unsupervised hier-
archical clustering that was performed on 948 differentially expressed tran-
Coon et al Evolving Technology/Basic Science
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Schemotactic agents for T cells but have also been shown to
have antiapoptotic activity17 and have been implicated as
promoters of metastasis and cancer progression, as have
CXCL12 and CXCL13.18
Interestingly, the gene list from group AS shows signifi-
cant enrichment for cell-surface receptors associated with
natural killer (NK) cell–mediated cytotoxicity. Several other
members of this pathway are also represented (Table 1). Fur-
ther support for NK cell enrichment comes from the obser-
vation that NK cells are known to be prolific producers of
and responders to chemokines19 and are both coordinated
by, and producers of, the sole traditional cytokine identified
in the surgical intervention group, IFN-g. It is known that up
to 80% of NK cells display CD8 antigens on their surface,
and our analysis shows a significant upregulation of CD8
surface antigen, while lacking any measurable expression
of CD4. It is noteworthy that both IFN-g and all of these
killer cell lectin-like receptors are downregulated in re-
sponse to surgical intervention, suggesting a diminished
ability to orchestrate NK cell–mediated cytotoxicity and per-
haps serving as a measure of the immunosuppression known
to occur after surgical intervention.
Based on the gene expression profiles we obtained and
what is known about chemokine and cytokine expression,
as well as cell-type recruitment after surgical intervention,
we can propose a hypothetical scenario to describe our ob-
served results. This hypothetical paradigm asserts that the
expression pattern we identified in the group undergoing
surgical intervention alone (group AS) marks a time point
in the acute inflammatory response at which a peripheral
cell population made up of predominantly neutrophils, NK
cells, or both expressing a variety of interleukin receptors
on their cell surfaces are activated by cytokines produced
by monocytes and macrophages at the wound site and begin
expressing a selection of chemokines whose cellular activi-
ties include the recruitment of lymphocytes to the wound
site, as well as immunosuppression of NK cell–mediated
cytotoxicity.
Although many of the body’s reactions to surgical injury
are meant to facilitate the healing process, some of the in-
flammatory consequences can have a negative effect on can-
cer progression in which a compromised immune system,
even for short periods, could have a significant deleterious
effect. At the time of surgical intervention, anesthetic and
surgically induced immune lethargy10 could allow forscripts identified in this investigation. This tool groups genes, experimental
conditions, or both into clusters based on the similarity of their expression
patterns. Using this approach, we demonstrated that the gene expression pat-
tern of the celecoxib-treated surgery group (group ACS) is more similar to
that of the baseline anesthesia group (group A) than that of the surgical in-
tervention–only group (group AS). However, unique gene expression pro-
files can be clearly delineated for each group.
diovascular Surgery c Volume 139, Number 5 1257
TABLE 1. A partial list of differentially expressed inflammatory genes
Gene
symbol
Fold change
(AS group)
Regulation
(group AS)
Fold change
(group ACS)
Regulation
(group ACS) Description
Differentially expressed genes: Cytokines and cytokine receptors
Ccl19 8.3 Up Mus musculus chemokine (C-C motif) ligand 19
Ccl2 2.8 Up Mus musculus chemokine (C-C motif) ligand 2
Ccl21c 64.7 Up Mus musculus chemokine (C-C motif) ligand 21c (leucine)
Ccl25 30.6 Up 2.5 Down Mus musculus chemokine (C-C motif) ligand 25
Ccl5 2.6 Down Mus musculus chemokine (C-C motif) ligand 5
Ccl8 7.0 Up Mus musculus chemokine (C-C motif) ligand 8
Ccr2 2.0 Up 3.2 Up Mus musculus chemokine (C-C motif) receptor 2
Ccr3 2.6 Down Mus musculus chemokine (C-C motif) receptor 3
Ccr9 5.6 Up Mus musculus chemokine (C-C motif) receptor 9
Cx3xl1 7.5 Up Mus musculus chemokine (C-X3-C motif) ligand 1
Cxcl13 4.9 Up Mus musculus chemokine (C-X-C motif) ligand 10
Cxcl13 2.5 Down Mus musculus chemokine (C-X-C motif) ligand 13
Cxcl16 3.3 Up Mus musculus chemokine (C-X-C motif) ligand 16
Cxcr3 2.3 Down Mus musculus chemokine (C-X-C motif) receptor 3
Differentially expressed genes: Interleukin receptors
Il18ap 2.1 Up Mus musculus interleukin 18 receptor accessory protein
Il1f9 2.6 Up 3.6 Up Mus musculus interleukin 1 family, member 9
Il1r1 3.1 Up Mus musculus interleukin 1 receptor, type I
Il1r2 5.7 Up 7.3 Up Mus musculus interleukin 1 receptor, type II
Il1rn 2.2 Up 3.2 Up Mus musculus interleukin 1 receptor, antagonist
Il28ra 7.8 Up Mus musculus interleukin 28 receptor, a
Il2rb 2.2 Down Mus musculus interleukin 2 receptor, b chain
Il8rb 2.8 Up 3.5 Up Mus musculus interleukin 8 receptor, b
Differentially expressed genes associated with natural killer cells
Ifng 3.1 Down Mus musculus interferon g
Klra3 2.2 Down Mus musculus killer cell lectin-like receptor, subfamily A, member 3
Klra8 2.7 Down Mus musculus killer cell lectin-like receptor, subfamily A, member 8
Klra9 2.2 Down Mus musculus killer cell lectin-like receptor, subfamily A, member 9
Klrb1c 2.6 Down Mus musculus killer cell lectin-like receptor, subfamily B, member 1C
Klrc2 2.7 Down Mus musculus killer cell lectin-like receptor, subfamily C, member 2
Klrd1 2.2 Down Mus musculus killer cell lectin-like receptor, subfamily D, member 1
Klrk1 3.7 Down Mus musculus killer cell lectin-like receptor, subfamily K, member 1
Fasi 2.8 Down Mus musculus Fas ligand (TNF superfamily, member 6)
Sh2d1a 2.3 Up Mus musculus SH2 domain protein 1A
Differentially expressed genes associated with macrophages and dendritic cells
Il1b 3.1 Up Mus musculus interleukin 1 b
Chi3l3 5.5 Up Mus musculus chitinase 3–like 3
Lst1 2.0 Up Mus musculus leukocyte-specific transcript 1
Ctsc 2.1 Up Mus musculus cathepsin C
Mpeg1 2.1 Up Mus musculus macrophage-expressed gene 1
Plscr1 2.1 Up 2.1 Up Mus musculus phospholipid scramblase 1
Rab11fip1 2.4 Up Mus musculus RAB11 family–interacting protein (class I)
S100a6 2.1 Up Mus musculus S100 calcium-binding protein A6 (calcyclin)
Sirpa 2.0 Up Mus musculus signal-regulator protein a
Mmp9 2.2 Up 2.7 Up Mus musculus matrix metallopeptidase 9
Clec4a2 2.6 Up Mus musculus C-type lectin domain family 4, member a2
Clec4a3 2.3 Up Mus musculus C-type lectin domain family 4, member a3
Clec4e 3.2 Up Mus musculus C-type lectin domain family 4, member e
Clec7a 2.4 Up Mus musculus C-type lectin domain family 7, member a
Evolving Technology/Basic Science Coon et al
E
T
/B
Scirculating tumor cell escape and metastatic seeding, as
well as providing a growth-promoting microenvironment
of any quiescent micrometastases already present. Because1258 The Journal of Thoracic and Cardiovascular SurCOX-2 inhibitors have the potential for modulating the
negative effects of the systemic response to surgical inter-
vention through their antiangiogenic, proapoptotic, andgery c May 2010
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Santimetastatic properties, we postulated that perioperative
administration of these compounds could mitigate some of
the increases in gene expression observed after surgical in-
tervention. To this end, we compared the gene expression
profile of our mice subjected to anesthesia (group A) with
that of a group of mice subjected to anesthesia followed
by our same surgical procedure but also receiving a regimen
of the US Food and Drug Administration–approved COX-2
inhibitor celecoxib around the time of surgical intervention
(group ACS).
Effect of Perioperative Celecoxib Administration
(Group ACS)
Perioperative administration of celecoxib for 3 days be-
fore surgical intervention had a profound effect on the ex-
pression of the 867 transcripts that were shown to be
differentially expressed in response to surgical intervention
(Figure 2, B). The vast majority of transcripts upregulated
in response to surgical intervention (group AS) were main-
tained near baseline levels in the celecoxib-treated group
(group ACS). The largest change was seen in the chemokine
Ccl25, which was 39.4-fold upregulated in response to sur-
gical intervention and 2.5-fold downregulated with the addi-
tion of celecoxib. All the chemokines and all but one (Ccr2)
of their receptorswere significantly downregulated as a result
of celecoxib treatment. Given that chemokine expression of
the sort seen in the surgical intervention group has frequently
been linked to metastasis and cancer recurrence,18,20 this
downregulation of chemokines could represent a potential
mechanism for the COX-2–independent antitumor effects
of celecoxib that we previously observed.21 Thus, this inves-
tigation supports the hypothesis that perioperative modula-
tion of the surgical stress response is possible with this
agent and provides the foundation for further study in this
area.
Based on the Venn diagram analysis (Figure 3), only 81
transcripts can be inferred to be differentially expressed in
the celecoxib-treated group outside of the context of surgical
intervention. Although unknown variables could have some
effect, it is reasonable to assume that the changes observed in
these 81 transcripts are primarily the result of the drug treat-
ment. Most of these 81 genes are related to the inflammatory
response. Most notable among them is Il1b, an important cy-
tokine in the inflammatory response that is produced by ac-
tivated macrophages. It stimulates thymocyte proliferation
by inducing IL-2 release, B-cell maturation and proliferation,
and fibroblast growth factor activity, all important agents of
immune integrity. Although not addressed in the current
study, the identification of these 81 transcripts suggests
that the effect of celecoxib on gene expression is not limited
to modulation of the surgical stress response, and our labora-
tory is actively investigating these additional consequences.
Other interesting genes include mediators of dendritic cell
differentiation, maturation, or both (Clec4a and Lst1);The Journal of Thoracic and Carenhancers of cytokine production in macrophages and den-
dritic cells (Clec7a, Plscr1, and Tirap); macrophage markers
(Ctsc and Mpeg1); mediators of phagocytosis (Rab11fip1,
S100A6, and Sirpa); and Chi3l3, a secreted protein that is
produced primarily by macrophages during inflammation.22
Interaction between Chi3l3 and Mmp9, which is also
expressed in the celecoxib-treated group, has been shown
to facilitate clearance of inflammatory cells in lung tissue
through a mechanism of Mmp9-dependent cleavage-
mediated modulation of Chi3l3’s chemotactic activity.23
Although it is necessary to further investigate the signifi-
cance of these findings, it is attractive to speculate that the
dramatic anti-inflammatory effect observed in the peripheral
blood of the celecoxib-treated group can be attributed to this
mechanism.
Perhaps most interesting is what is no longer expressed af-
ter celecoxib treatment (groupACS). The proposed immuno-
suppression characterized by downregulation of the killer
cell lectin-like receptors was mitigated by celecoxib treat-
ment, as was the considerable chemokine response that has
been implicated in metastasis and cancer progression. Addi-
tionally, it is quite fascinating that although the gene list from
the surgical intervention–only group (group AS) implies
a cell population composed of predominantly NK cells, the
gene list from the celecoxib-treated surgical intervention
group (group ACS) appears to indicate a cell population
more characteristic of dendritic cells and macrophages.
Although the significance of these results remains com-
plex, we can propose a hypothetical scenario to account
for our observed results. This paradigm contends that cele-
coxib treatment modulates some of the negative effect of
surgical intervention by modifying gene expression, possi-
bly mediating surgical intervention–induced immunosup-
pression (as suggested by the changes induced in the killer
cell lectin-like receptors), and/or mediating the expression
of protumorigenic genes (eg, chemokines). Additionally,
celecoxib treatment appears to result in a shift of predomi-
nant peripheral cell type from neutrophils, NK cells, or
both to monocyte/macrophages, dendritic cells, or both, at
least at the 6-hour time point. This shift is evidenced by
the replacement of IFN-g with interleukin 1B, increased ex-
pression of a variety of macrophage and dendritic cell sup-
port genes, and an increase in the expression of genes
involved in phagocytotic gene function. Based on a timeline
of cell-type recruitment whereby neutrophils are the major
leukocyte subpopulation immediately after surgical inter-
vention,24 followed by an increase in monocyte and macro-
phage numbers,25 this proposed shift might also represent an
overall increase in the rate at which the surgical stress re-
sponse resolves, shortening the time in which a patient is ex-
posed to the detrimental effects of perioperative immune
suppression.
This study is limited by our assessment of genomic pro-
files at a single time point after surgical intervention.diovascular Surgery c Volume 139, Number 5 1259
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SObviously, the response to surgical intervention is repre-
sented by a continuum of differential gene expression, which
would require a more in-depth analysis using multiple time
points. Furthermore, we have attempted to study the sys-
temic response by means of mRNA profiling of peripheral
blood, which does not take into account proteins already ex-
pressed/secreted by local inflammatory cells, circulating
cells, or both. It should also be noted that mRNA from
whole-blood preparations can be affected by variation in leu-
kocyte populations. Despite this limitation, the use of whole
blood for assessment of gene expression has been validated
in hundreds of studies. Additionally, we did not directly
measure the effect of celecoxib in this study (ie, there was
no celecoxib-only group), necessitating reliance on infer-
ence in our interpretation of the effects of celecoxib outside
of the context of surgical intervention. This, however, was
not the focus of this investigation and will be addressed in
subsequent studies. Lastly, the experiment was performed
on young mice. Although older mice might have a different
immune response than younger mice, all our experiments
were performed onmice of similar ages, and therefore the re-
sponse to celecoxib is still valid. While recognizing these
limitations, we believe that this research represents a valu-
able contribution to the overall understanding of the effect
of surgical wounding and its role in cancer progression.
In summary, our data show that there is a remarkable dif-
ferential gene expression induced by surgical intervention,
as evidenced by whole genomic profiling of peripheral blood
6 hours after a surgical injury. Additionally, the periopera-
tive administration of the COX-2 inhibitor celecoxib pro-
foundly affects this response. This is the first attempt, to
our knowledge, to investigate these phenomena at the geno-
mic level. Although in-depth analysis of all involved genes
and pathways is beyond the scope of this article, we believe
that many of the potentially deleterious effects of the surgi-
cal stress response that have been shown to promote tumor-
igenesis can be mitigated through the use of perioperative
celecoxib treatment. Although ongoing animal and human
studies are currently being carried out in our laboratory to
fully evaluate the consequences of pharmacologic interven-
tion of the surgical stress response, the preliminary data pre-
sented here appear to support its potential use.
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FIGURE E1. Pathway analysis was performed in both GeneSpring and through BioRag (www.biorag.org) by using the BioCarta, KEGG, and GenMAPP
databases. The figure shows the results of these analyses for the surgical intervention group (group AS). Pink ovals represent proteins in the pathways, and
those highlighted in blue are represented in our experimental gene list. It can be seen that the central mediator of the resulting pathways is interferon g (Ifng)
and that the most significant pathways (displayed as blue diamonds) are transcription (connectivity 6474), angiogenesis (connectivity 2735), pathogenesis
(connectivity 1639), chemotaxis (connectivity 898), evasion or tolerance of host immune response (connectivity 35), and evasion or tolerance of host
immune response of other organisms during symbiotic interaction (connectivity 35). An anaphase-promoting complex (connectivity 477) can also be ob-
served. Other significant pathways observed, although too numerous to list fully, include apoptotic signaling in response to DNA damage, antiapoptotic sig-
naling from Igf1r, TH2-mediated cytokine gene expression, RAS signaling, G1 to S transition, mitogen-activated protein kinase activation, and T-cell
activation. Gene Ontology (GO) is a database that assimilates all available information to categorize genes according to function. A search for GO associations
within the 867 transcripts identified in the surgical intervention group revealed significant levels of GO enrichment (P< .05). Not surprisingly, many of the
transcripts that were differentially expressed in response to surgical intervention were associated with the surgical stress response. Other biological processes
observed were cell division, cell cycle, DNA replication, development, cytoskeletal organization, and chemotaxis. It should be noted that these functional
categories are not exclusive, and many transcripts belong to more than 1 category.
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FIGURE E2. Pathway analysis was performed in both GeneSpring and with BioRag (www.biorag.org) by using the BioCarta, KEGG, and GenMAPP
databases. This figure shows the results of these analyses for the celecoxib-treated surgical intervention group (group AS). Pink ovals represent proteins
in the pathways, and those highlighted in blue are represented in our experimental gene list. It can be seen that the central mediator of the resulting pathways
is interleukin 1b (Il1b) and that the most significant pathways (displayed as gold diamonds) are tumor nuclear factor (NF) kB transcription factor activity
(connectivity 1438) and tumor necrosis factor production (connectivity 1079). Additionally, this gene list is associated with 2 enzymes (displayed as purple
sickles): phospholipase C and protein tyrosine kinases. Fewer but still significant (P<.05) Gene Ontology (GO) enrichment associations were found among
the 216 transcripts identified in the celecoxib-treated group, and many of the same biological processes related to the surgical stress response identified in the
above comparison were represented here as well, albeit at lower frequencies. Interestingly, this group contained a biological process not found in the surgical
intervention group: regulation of phagocytosis/endocytosis. Subsequent analysis revealed that this phagocytosis/endocytosis function was contained within
the 81 transcripts mediated solely by celecoxib.
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